Chikungunya Global Market Report 2025

Chikungunya (CHIKV) is a viral infection caused by the chikungunya virus, primarily transmitted to humans through the bites of infected Aedes aegypti and Aedes albopictus mosquitoes. The infection causes symptoms such as fever, joint pain, headache, rash, and muscle pain, which significantly affect the quality of life of those who are infected.

The main product types for chikungunya include antiviral drugs, herbal and complementary treatments, supportive care, and vaccines. Antiviral drugs are designed to prevent or treat viral infections by inhibiting the replication of viruses in the body. These medications come in various forms, such as liquids, powders, and solids, and are used at different stages of the disease, including acute, chronic, and post-infection stages. These products are distributed through a variety of sales channels, including hospital pharmacies, online pharmacies, retail pharmacies, and supermarkets, and are used by various end users such as caregivers, healthcare professionals, and patients.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The chikungunya market research report is one of a series of new reports from The Business Research Company that provides chikungunya market statistics, including the chikungunya industry global market size, regional shares, competitors with the chikungunya market share, detailed chikungunya market segments, market trends, and opportunities, and any further data you may need to thrive in the chikungunya industry. This chikungunya market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The chikungunya market size has grown strongly in recent years. It will grow from $0.59 billion in 2024 to $0.65 billion in 2025 at a compound annual growth rate (CAGR) of 9.4%. The growth in the historic period can be attributed to increasing per capita healthcare expenditures, growing prevalence of emerging and re-emerging infectious diseases, increasing personal disposable income, climate change, and increasing awareness regarding mosquito disease.

The chikungunya market size is expected to see strong growth in the next few years. It will grow to $0.92 billion in 2029 at a compound annual growth rate (CAGR) of 9.2%. The growth in the forecast period can be attributed to an international boost in clinical trials, a growing geriatric population, a rising need for immunization, increasing government and non-government initiatives, increasing government investments, and favorable policies. Major trends in the forecast period include advancements in biotechnology for vaccine development, new vaccine opportunities, CRISPR and AI for innovative solutions, strategic collaborations among pharmaceutical players, and integration of telemedicine services.

The forecast of 9.2% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may pose challenges for U.S. tropical medicine by restricting access to rapid diagnostic tests and antiviral medications imported from Brazil and Singapore, potentially delaying outbreak responses and increasing public health expenditures. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing prevalence of mosquito-borne diseases is expected to drive the growth of the chikungunya market in the coming years. Mosquito-borne diseases, including chikungunya, dengue, and the Zika virus, are transmitted to humans through infected Aedes mosquitoes and present significant global public health challenges. The rising incidence of these diseases is influenced by factors such as climate change, urbanization, deforestation, stagnant water accumulation, insufficient vector control measures, increased global travel, and insecticide resistance. Chikungunya treatment helps patients by alleviating symptoms such as fever, joint pain, and inflammation, improving overall comfort and mobility, reducing complications, and promoting recovery through hydration, pain management, and supportive care. For instance, in December 2024, the UK Health Security Agency reported that between January and June 2024, the number of dengue cases among returning travelers in England, Wales, and Northern Ireland surged to 473, a 201% increase compared to the 157 cases reported during the same period in 2023. This growing global incidence of mosquito-borne diseases is fueling the growth of the chikungunya market.

Leading companies in the chikungunya market are focusing on the development of innovative vaccines to enhance immunity, prevent disease outbreaks, and address the rising global health burden of chikungunya virus infections. One such innovation is the live attenuated chikungunya vaccine, which uses a weakened form of the virus to stimulate an immune response without causing the disease, providing long-term protection. For example, in November 2023, Valneva SE, a France-based biotechnology company, announced the approval of IXCHIQ, a live attenuated chikungunya vaccine, by the U.S. Food and Drug Administration (FDA). This approval was granted under accelerated approval based on anti-CHIKV neutralizing antibody titers, with continued approval contingent on confirming clinical benefits in further studies. Valneva also received a Priority Review Voucher (PRV) from the FDA, which it plans to monetize to support its research and development efforts. IXCHIQ is administered as a single-dose injection and contains a live, weakened form of the chikungunya virus, which may cause mild symptoms similar to the disease.

In February 2023, Bavarian Nordic A/S, a Denmark-based biotechnology company, acquired the travel vaccine portfolio from Emergent BioSolutions Inc. for USD 380 million. This acquisition aims to strengthen Bavarian Nordic's position in the travel vaccine market by adding marketed vaccines such as Vivotif for typhoid fever prevention, Vaxchora for cholera prevention, and a phase 3 vaccine candidate for chikungunya virus prevention. Emergent BioSolutions Inc., a US-based life sciences company, also offers chikungunya vaccines.

Major players in the chikungunya market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Thermo Fisher Scientific Inc., Takeda Pharmaceutical Company Limited, Quest Diagnostics Incorporated, Eurofins Scientific SE, Grifols Diagnostic Solutions Inc., bioMerieux SA, Bio-Rad Laboratories Inc., DiaSorin S.p.A., Euroimmun AG, Evotec SE, Valneva SE, ELITechGroup S.A.S., Vaxart Inc., BioPerfectus Biotechnology Co. Ltd., CTK Biotech Inc., Creative Diagnostics Inc., Inovio Pharmaceuticals Inc., Biotrol Laboratories Pvt. Ltd.

North America was the largest region in the chikungunya market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in chikungunya report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the chikungunya market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The chikungunya market consists of revenues earned by entities by providing services such as vaccination services, diagnostic testing services, and consultation and medical care. The market value includes the value of related goods sold by the service provider or included within the service offering. The chikungunya market also includes sales of vaccines, diagnostic kits, supportive therapies, and diagnostic equipment. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Chikungunya Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on chikungunya market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for chikungunya ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The chikungunya market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Antiviral Drugs; Herbal And Complementary Treatments; Supportive Care; Vaccines
• 2) By Product Form: Liquid Form; Powder; Solid Form
• 3) By Disease Stage: Acute; Chronic; Post-Infection
• 4) By Sales Channel: Hospital Pharmacies; Online Pharmacies; Retail Pharmacies; Supermarkets
• 5) By End User: Caregivers; Healthcare Professionals; Patients
• Subsegments:
• 1) By Antiviral Drugs: Nucleoside Analogues; Protease Inhibitors
• 2) By Herbal And Complementary Treatments: Ayurvedic Remedies; Homeopathic Treatments; Traditional Chinese Medicine
• 3) By Supportive Care: Pain Relievers (NSAIDs, Acetaminophen); Fluid Therapy; Physiotherapy
• 4) By Vaccines: Live-Attenuated Vaccines; Inactivated Vaccines; mRNA-Based Vaccines
• Companies Mentioned: F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; Thermo Fisher Scientific Inc.; Takeda Pharmaceutical Company Limited; Quest Diagnostics Incorporated; Eurofins Scientific SE; Grifols Diagnostic Solutions Inc.; bioMerieux SA; Bio-Rad Laboratories Inc.; DiaSorin S.p.A.; Euroimmun AG; Evotec SE; Valneva SE; ELITechGroup S.A.S.; Vaxart Inc.; BioPerfectus Biotechnology Co. Ltd.; CTK Biotech Inc.; Creative Diagnostics Inc.; Inovio Pharmaceuticals Inc.; Biotrol Laboratories Pvt. Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.